FDA vs. FTC: Why Two Different Federal Agencies Oversee Stem Cell Clinic Claims — and What Each One Catches

What this article covers
- Two Watchdogs, Two Different Jobs
- The FDA's job is to regulate the biological product itself: whether it's lawfully marketed, manufactured under appropriate controls, and backed by an approved application where one is required. The FTC's job is different.
- The Legal Standard Behind "Unsubstantiated"
- When regulators or advertising-law attorneys describe a health claim as "unsubstantiated," they are usually invoking a specific legal bar: advertisers must possess "competent and reliable scientific evidence" before making an objective claim about a health product's safety or effectiveness. The FTC laid this standard out in detail in its Health Products Compliance Guidance, published in December 2022, which updated decades-old guidance to make clear that for claims about treating or curing a disease, the agency generally expects well-controlled human clinical testing — not testimonials, animal data, or a plausible biological mechanism alone.
- What FTC Cases Have Actually Targeted
- The FTC's stem cell enforcement history, though still limited compared with its action in other health categories, has followed a consistent pattern.
- What an FTC Action Does — and Doesn't — Tell You
- An FTC complaint or settlement reflects the agency's view of past advertising by a specific business at a specific time. It doesn't certify that a clinic's underlying medical product is safe or unsafe, and the absence of any FTC action against a given provider is not evidence that its claims meet the substantiation standard — only that enforcement hasn't reached it yet, if it ever will.
- Where to Check and Report
- The FTC's enforcement actions and administrative complaints are searchable through its public case and news archives. gov.
Most consumer guidance about evaluating a stem cell clinic focuses on the FDA — whether a product is lawfully regulated, whether the clinic has received a warning letter, whether an IRB has approved a protocol. But a second federal agency, the Federal Trade Commission, has its own, separate legal standard that applies to almost every stem cell clinic in the country: the truthfulness of what it says in its advertising. Understanding what the FTC actually polices, what its past enforcement actions have targeted, and what its standard for "proof" requires can give you a sharper lens for reading a clinic's website, seminar pitch, or sales materials — independent of whatever the FDA may or may not have said about the underlying product.
Two Watchdogs, Two Different Jobs
The FDA's job is to regulate the biological product itself: whether it's lawfully marketed, manufactured under appropriate controls, and backed by an approved application where one is required. The FTC's job is different. Under Section 5 of the FTC Act, it has authority to act against "unfair or deceptive acts or practices" in commerce — which, for a health-related business, means the marketing claims, testimonials, seminar pitches, and advertising copy a clinic uses to sell its services. A business can draw FTC scrutiny over how it advertises a treatment even when the treatment itself isn't the primary subject of an FDA action. The two agencies sometimes act in parallel, but neither one's silence tells you what the other would say.
The Legal Standard Behind "Unsubstantiated"
When regulators or advertising-law attorneys describe a health claim as "unsubstantiated," they are usually invoking a specific legal bar: advertisers must possess "competent and reliable scientific evidence" before making an objective claim about a health product's safety or effectiveness. The FTC laid this standard out in detail in its Health Products Compliance Guidance, published in December 2022, which updated decades-old guidance to make clear that for claims about treating or curing a disease, the agency generally expects well-controlled human clinical testing — not testimonials, animal data, or a plausible biological mechanism alone. That bar is worth remembering any time a clinic's marketing describes "results" rather than "data."
What FTC Cases Have Actually Targeted
The FTC's stem cell enforcement history, though still limited compared with its action in other health categories, has followed a consistent pattern. Public case records and FTC press materials describe:
- Claims that stem cell injections could treat or reverse symptoms of serious, unrelated conditions (autism and vision loss have both appeared in FTC case materials) without supporting clinical evidence.
- Claims that cell therapy was "comparable or superior" to FDA-approved treatments, surgery, or standard pain medications.
- Marketing funnels that used free educational seminars — sometimes aimed at older adults — to generate paid consultations and high-cost injections, often in the thousands of dollars per joint or session.
- Use of individual patient anecdotes and dramatic before/after stories as the primary evidence offered for a treatment's effectiveness.
One of the agency's earliest actions in this category, announced in 2018, led to a settlement of roughly $3.3 million against two stem cell centers; a separate 2019 action resulted in roughly $515,000 being returned directly to consumers who had purchased amniotic stem cell therapy based on claims the FTC alleged were deceptive. These are illustrative of the kinds of claims that have drawn scrutiny — not a complete catalogue, and not a reason to assume any specific clinic today is or isn't compliant.
What an FTC Action Does — and Doesn't — Tell You
An FTC complaint or settlement reflects the agency's view of past advertising by a specific business at a specific time. It doesn't certify that a clinic's underlying medical product is safe or unsafe, and the absence of any FTC action against a given provider is not evidence that its claims meet the substantiation standard — only that enforcement hasn't reached it yet, if it ever will. Settlements are also frequently resolved without an admission of wrongdoing, which affects how much can be inferred from them.
Questions to Ask Yourself About a Clinic's Marketing
- Does the claim describe a specific disease outcome ("treats," "reverses," "cures") without citing a specific, named clinical trial?
- Is a personal testimonial or single dramatic case being used as if it were data?
- Does the pitch compare the treatment favorably to surgery, medication, or an FDA-approved therapy without a cited head-to-head study?
- Is the offer being presented through a free seminar, webinar, or high-pressure consultation funnel aimed at an older or chronically ill audience?
- Would the claim survive being rewritten as "a well-controlled clinical trial has shown X"? If not, treat it as unproven.
Where to Check and Report
The FTC's enforcement actions and administrative complaints are searchable through its public case and news archives. Consumers who believe they have encountered a deceptive health claim can file a report directly with the agency through its consumer complaint portal, ReportFraud.ftc.gov. Filing doesn't guarantee an investigation, but these reports feed the pattern-recognition that has led to past enforcement.
Bottom Line
The FDA and FTC ask different questions about the same clinic: one about the product, one about the pitch. A clean FDA record says nothing about whether a clinic's advertising meets the FTC's evidentiary bar, and vice versa. Reading marketing claims with the "competent and reliable scientific evidence" standard in mind — and treating testimonials, seminar pitches, and cure-sounding language as signals rather than proof — is one more independent check you can run before trusting what a clinic says about itself.
Key Questions Answered
- What is the difference between FDA and FTC oversight of stem cell clinics?
- The FDA regulates the biological product itself; the FTC, under Section 5 of the FTC Act, polices whether a clinic's advertising and marketing claims are truthful.
- What evidence does the FTC expect for disease-treatment claims?
- "Competent and reliable scientific evidence"; its 2022 Health Products Compliance Guidance says disease claims generally need well-controlled human clinical testing, not testimonials or animal data.
- What have FTC stem cell cases involved?
- Unsupported claims for conditions like autism and vision loss, a roughly $3.3 million 2018 settlement against two centers, and about $515,000 returned to consumers in 2019.
Sources
- Health Products Compliance Guidance, Federal Trade Commission, 2022 — https://www.ftc.gov/system/files/ftc_gov/pdf/Health-Products-Compliance-Guidance.pdf
- FTC Returns Almost $515,000 to Consumers Who Bought Deceptively Marketed Amniotic Stem Cell Treatments, Federal Trade Commission, 2019 — https://www.ftc.gov/news-events/press-releases/2019/04/ftc-returns-almost-515000-consumers-who-bought-deceptively
- FTC Acts for the First Time Against Marketers of Stem Cell Therapies, Federal Trade Commission press release summary, 2018 — https://www.ftc.gov/node/47462
- Federal Trade Commission Acts for First Time Against Stem Cell Clinics, Pew Charitable Trusts, 2018 — https://www.pewtrusts.org/en/research-and-analysis/articles/2018/12/21/federal-trade-commission-acts-for-first-time-against-stem-cell-clinics
- FTC Fines 2 Stem Cell Centers $3.3M for Advertising Unproven Treatments, Becker's Hospital Review, 2018 — https://www.beckershospitalreview.com/quality/ftc-fines-2-stem-cell-centers-3-3m-for-advertising-unproven-treatments
- Federal Trade Commission Takes Action Against Stem Cell Clinics (Georgia case summary), FTC case page, 2021 — https://www.ftc.gov/node/73943
- FTC Announces New Fraud Reporting Platform for Consumers, ReportFraud.ftc.gov, Federal Trade Commission, 2020 — https://www.ftc.gov/news-events/news/press-releases/2020/10/ftc-announces-new-fraud-reporting-platform-consumers-reportfraudftcgov
Related Articles
- Research & Industry
Does Insurance Cover Stem Cell Therapy? What Cash-Pay Pricing Really Signals About the Evidence
Most stem cell clinic treatments are cash-pay because they aren't FDA-approved, which means Medicare and private insurers won't reimburse them. Here's what that pricing model actually signals — and the questions it should prompt before you pay.
- Research & Industry
Peer-Reviewed, or Just Looks That Way? How to Vet the Research a Stem Cell Clinic Cites
Published citations vary widely in quality. Study design, journal vetting, conflicts of interest and corrections matter more than a peer-reviewed label alone.
- Research & Industry
Treatment Guarantees and Refund Policies at Stem Cell Clinics: What They Actually Mean
A clinic refund promise is a business policy, not clinical evidence. What guarantees may exclude, enforcement history and questions to ask before paying.